Chimeric Monoclonal Antibody ch806 for Targeted Tumor Immunotherapy
Author Information
Author(s): Panousis C, Rayzman V M, Johns T G, Renner C, Liu Z, Cartwright G, Lee F-T, Wang D, Gan H, Cao D, Kypridis A, Smyth F E, Brechbiel M W, Burgess A W, Old L J, Scott A M
Primary Institution: Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch
Hypothesis
Can a chimeric monoclonal antibody (ch806) effectively target tumors expressing de2-7 EGFR or amplified EGFR?
Conclusion
The ch806 antibody shows significant antitumor effects on tumors expressing de2-7 EGFR and warrants further investigation as a therapeutic agent.
Supporting Evidence
- Ch806 was stably expressed in CHO cells and retained the antigen binding specificity of the murine parental antibody.
- Ch806 demonstrated significant antitumor activity against xenografts expressing de2-7 EGFR.
- 111In-labelled ch806 showed superior tumor localization compared to 125I-labelled ch806.
- Ch806 exhibited strong antibody-dependent cellular cytotoxicity against target cells.
Takeaway
Scientists created a special antibody that can find and attack certain cancer cells without hurting normal cells, which could help treat tumors better.
Methodology
The study involved engineering a chimeric antibody, testing its binding affinity, and conducting in vivo therapy studies in mice with tumor xenografts.
Potential Biases
Potential bias in the selection of tumor models and the interpretation of antibody efficacy.
Limitations
The study primarily focused on animal models, and the results may not directly translate to human patients.
Participant Demographics
BALB/c nude mice were used for in vivo studies.
Statistical Information
P-Value
<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website